Company Analysis
Sign in

NuCana plc (NCNA)

Nasdaq: NCNA · Pharmaceutical Preparations · Edinburgh, GB · filing with the SEC since 2017
Full chart Alerts Compare
Grade5.0
◀ Past 4.3● Present 4.3▶ Future 6.1
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-£29.4M-54.5%
Earnings per share£0.00+100.0%
Operating cash flow-£7.5M+60.9%
Cash£24.3M+259.3%
Debtn/a
Shareholders’ equity£24.3M+308.6%
Shares, diluted11.23B+15038.7%
Return on equity-120.7%
The recordfrom its filings
Filings in 202624
Newest filingNov 12 · 6-K
Annual reportMar 19, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted33
Filer categoryNon-accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in GBP. Nothing here is a forecast.

News

Jun 24, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Jun 23, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Apr 16, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton NCNA · research, not advice